In a recent interview, Cleo Diagnostics CEO Dr. Richard Allman discussed the company’s path to revolutionise ovarian cancer screening.
The quest for early detection aligns with the urgent need to improve prognosis. “Ovarian cancer, like most solid tumours, can be very successfully treated with surgery if it’s caught early,” Allman said.
Cleo Diagnostics’ three phase approach to commercialisation begins with the deployment of a triage test designed to differentiate between ovarian cancer and benign conditions — streamlining clinical decision making for symptomatic women.
The follow-up recurrence test, as Allman described it, serves to monitor post-surgery patients for signs of cancer return, a plight faced by many within 18 months of initial treatment. The third phase is a general screening test for the broader population, which Allman dubbed the “holy grail in ovarian cancer.”
Crucial to Cleo Diagnostics’ strategy is nurturing investor confidence by unveiling progress metrics and providing regular updates. “We are a commercialisation company aiming to generate revenue at an early stage,” Allman highlighted, emphasising the company’s focus on moving beyond the research and development phase.
The company is collaborating with renowned cancer research entities and scientific publications that not only educate clinicians on the benefits of Cleo’s tests, but also facilitate the crucial inclusion of their product in clinical guidelines. Such visibility could drive widespread clinical adoption, thereby creating a self-reinforcing cycle of evidence-driven promotion and market penetration.
Cleo Diagnostics is also proactively laying down the infrastructure to ensure its tests quickly gain traction once approved. This includes engaging key opinion leaders and building clear pathways for clinic implementation, aiming to minimise the lag between US Food and Drug Administration approval and sales generation.
Watch the full interview with Cleo Diagnostics CEO Richard Allman above.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.
Leave a Reply